ClinicalTrials.gg
CompletedNCT04518293GMRx2_ACTUpdated Jun 3, 2025Results posted

Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension

A Phase 3 interventional study of Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg and telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg in Hypertension, sponsored by George Medicines PTY Limited. Completed at 89 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-03.

Sponsored by George Medicines PTY Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,385
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.

Enrollment
6th of 99
1,385 · median 184
Started
2021
with 2 others
Phase 3
40 of 99
none open now
Registered
89th of 99
by date
Lead sponsor
2 of 99
George Medicines PTY Limited

Among the 99 studies testing telmisartan in Hypertension, this one is the 6th largest by enrollment, is one of 3 that started in 2021, is one of 40 in phase 3, and was the 89th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About telmisartan

Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies testing telmisartan in Hypertension, or all of them as a file.
02

Study summary

Recent hypertension guidelines recommend combination therapy as initial treatment for many or most patients. Several trials suggest triple low-dose combination therapy may be highly effective in terms of achieving blood pressure (BP) control without increasing adverse effects. This trial is designed to investigate the efficacy and safety of GMRx2 in participants with high blood pressure compared to dual combinations.

Read the detailed description

TRIAL DRUG:

GMRx2: Single pill combinations of telmisartan/amlodipine/indapamide Dose version 2: telmisartan 20mg/amlodipine 2.5mg/indapamide 1.25mg Dose version 3: telmisartan 40mg/amlodipine 5 mg/indapamide 2.5mg INDICATION: Hypertension TRIAL DESIGN: International, multicenter, randomized, double-blind, active controlled, parallel-group.

OBJECTIVES: To investigate the efficacy and safety of GMRx2 compared to dual combinations

INTERVENTION:

Single-Blind Active Run-In Period. Enrolled participants will be asked to discontinue their current BP-lowering drug(s) and undergo a single-blind active run-in period for 4 weeks with GMRx2 dose version 2. Participants will be advised to take the capsule once daily in the morning at approximately the same time each day. For days on which BP is being measured, the capsule should be taken directly after the morning home BP measurement.

Double-Blind Treatment Period. Participants still eligible after the run-in period will be allocated in a double-blind fashion to one of the following 4 randomized groups: GMRx2 dose version 2, or telmisartan 20mg+amlodipine2.5mg, or telmisartan 20mg+indapamide 1.25mg, or amlodipine 2.5mg+indapamide 1.25mg. At week 6 all doses will be doubled.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

At screening visit

  1. Provided signed consent to participate in the trial.
  2. Adult of age ≥18 years.
  3. Attended automated clinic seated mean systolic blood pressure (SBP) (average of last 2 measurements calculated by the device):

140-179 mmHg on 0 BP-lowering drugs, or 130-170 mmHg on 1 BP-lowering drug, or 120-160 mmHg on 2 BP-lowering drugs, or 110-150 mmHg on 3 BP-lowering drugs.

At randomization visit

  1. Home seated mean SBP 110-154 mmHg in the week prior to the randomization visit.
  2. Adherence of 80-120% to run-in medication.
  3. Tolerated run-in medication.
  4. Adherence to home BP monitoring schedule: in the week before randomization, at least 6 measures (e.g. ≥2 sets of triplicate measures, ≥3 sets of duplicate measures) including at least 1 morning and 1 evening each with ≥2 measures. Morning is defined as any measure in the am and evening as any measure in the pm. Morning and evening do not have to be same day.

Exclusion criteria

Exclusion Criteria:

At screening visit

  1. Receiving 4 or more BP-lowering drugs.
  2. Receiving any BP lowering drugs for indications other than hypertension e.g. heart failure
  3. Pregnant or had a positive pregnancy test or unwilling to undertake a pregnancy test during the trial and up to 30 days after the discontinuation of the trial medication or breastfeeding or of childbearing age and not using an acceptable method of . Acceptable methods of birth control include hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method (e.g. condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel), or male partner sterilization. Contraception should be used for at least 1 month before the screening visit and until the end of trial participation.
  4. Not suitable for participation in a clinical trial according to local ethical or regulatory requirements related to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
  5. , including (e.g. anaphylaxis or angioedema), to the active run-in treatment or to any of the trial medication options in the four randomized groups.
  6. Current/history of , stroke, or hypertensive encephalopathy.
  7. Current/history of acute coronary syndrome, unstable angina, myocardial infarction, percutaneous transluminal coronary revascularization, or coronary artery bypass graft.
  8. Current atrial fibrillation. Patients with a history of paroxysmal atrial fibrillation are potentially eligible as long as there has been no episode in the last 3 months, while patient with a history of persistent or permanent atrial fibrillation are not eligible.
  9. Current/history of class III and IV congestive heart failure.
  10. Current/history of a known secondary cause of hypertension, such as primary aldosteronism, renal artery stenosis, pheochromocytoma, or Cushing's syndrome.
  11. Current/history of substantially uncontrolled diabetes ( > 11.0%) within last three months.
  12. Current/history of end-stage renal disease or anuria or estimated (eGFR) \<60 ml/min/1.73m2.
  13. Electrolyte levels that would be regarded as contraindications for any of the potential treatment arms e.g. serum sodium \<132mmol/l or >148mmol/l serum potassium \<3.1 mmol/l or >5.6 mmol/l.
  14. Current/history of (AST) or alanine aminotransferase (ALT) >3 times the within 6 months.
  15. Current concomitant illness or physical impairment or mental condition that in the judgment of the investigator could interfere with the effective conduct of the trial or constitutes a significant risk to the participants' well-being.
  16. Arm circumference that is too large (>55 cm) or too small (\<15-24 cm) to allow accurate measurement of BP.
  17. Currently taking or might need during the trial, a concomitant treatment which is known to interact with one or more of the trial medications: digoxin, lithium, diabetics receiving aliskiren, moderate and strong inhibitors (e.g. ritonavir, ketoconazole, diltiazem], simvastatin >20 mg/day, .
  18. Might need treatment with drugs that are prohibited during the trial: other antihypertensive drugs, endothelin receptor antagonists, neprilysin inhibitors, or other drugs that may affect BP.
  19. Current surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of trial drugs such as prior major gastrointestinal tract surgery (e.g. gastrectomy, lap band, or bowel resection) or acute flare of inflammatory bowel disease within one year.
  20. Individuals working >2 nightshifts per week.
  21. Participated in any investigative drug or device trial within the previous 30 days.
  22. History of alcohol or drug abuse within 12 months.

At randomization visit

  1. Unable to adhere to the trial procedures during the run-in treatment period.
  2. Any of the following which in the investigator's judgment may compromise the safety of the participant if randomized to the trial medications:

    1. High or low clinic BP levels even in the light of the values for home BP that are available for that participant. The exact levels of BP are not specified, since there is clinical uncertainty as to the relevance of BP levels which are high or low in clinic only; for example, the clinical relevance of 'whitecoat hypertension' is uncertain.
    2. High or low home diastolic BP (DBP) levels. The exact levels of DBP is not specified, reflecting clinical uncertainty of the implications of isolated diastolic hypertension. However, home DBP values of >99 mmHg may typically be considered as requiring treatment intensification, and such participants would not be suitable for randomization.
    3. Any abnormal laboratory value which in the judgment of the investigator could interfere with the effective conduct of the trial or constitutes a significant risk to the participants' well-being.
    4. Fulfilling any of the exclusion criteria mentioned for the screening visit, when verified again at randomization visit.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,385 participants (actual)

Study arms

  • Experimental
    GMRx2

    Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg

    Drug: Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg · Drug: telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg

  • Active comparator
    Dual - TA

    Telmisartan 20 mg/amlodipine 2.5 mg . At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg

    Drug: Telmisartan 20 mg/amlodipine 2.5 mg · Drug: telmisartan 40 mg/amlodipine 5 mg

  • Active comparator
    Dual - TI

    Telmisartan 20 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to telmisartan 40 mg/indapamide 2.5 mg

    Drug: Telmisartan 20 mg/indapamide 1.25 mg · Drug: telmisartan 40 mg/indapamide 2.5 mg

  • Active comparator
    Dual - AI

    Amlodipine 2.5 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to amlodipine 5 mg/indapamide 2.5 mg

    Drug: Amlodipine 2.5 mg/indapamide 1.25 mg · Drug: amlodipine 5 mg/indapamide 2.5 mg

Interventions

  • DrugTelmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg

    Drug page: Telmisartan

    Single pill

  • Drugtelmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg

    Drug page: Telmisartan

    Single pill

  • DrugTelmisartan 20 mg/amlodipine 2.5 mg

    Drug page: Telmisartan

    oral tablet

  • Drugtelmisartan 40 mg/amlodipine 5 mg

    Drug page: Telmisartan

    oral tablet

  • DrugTelmisartan 20 mg/indapamide 1.25 mg

    Drug page: Telmisartan

    oral tablet

  • Drugtelmisartan 40 mg/indapamide 2.5 mg

    Drug page: Telmisartan

    oral tablet

  • DrugAmlodipine 2.5 mg/indapamide 1.25 mg

    Drug page: Amlodipine

    oral tablet

  • Drugamlodipine 5 mg/indapamide 2.5 mg

    Drug page: Amlodipine

    oral tablet

06

What researchers measure

Primary outcomes

  1. Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12

    The primary outcome measure is difference in change in average home SBP for GMRx2 vs each dual combination evaluated from randomization to Week 12. The change in home SBP from randomization for all treatment arms was measured using least squares (LS) mean change. The pairwise comparisons between GMRx2 and dual treatments in change in home SBP were estimated using LS means difference and are described in the statistical analysis.

    Time frame: Week 12

Secondary outcomes

  1. Difference in Change in Clinic Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12

    Difference in change in average clinic SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 12.

    Time frame: Week 12

  2. Difference in Change in Clinic Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 6

    Difference in change in average clinic SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6.

    Time frame: Week 6

  3. Difference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 12

    Difference in change in average clinic DBP for GMRx2 vs each dual combination was evaluated from randomization to Week 12.

    Time frame: Week 12

  4. Difference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 6

    Difference in change in average clinic DBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6.

    Time frame: Week 6

  5. Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and Diastolic Blood Pressure (DBP) <90 mmHg at Week 12

    The percentage of participants achieving averaged clinic SBP \<140 mmHg and DBP \<90 mmHg at Week 12 was evaluated.

    Time frame: Week 12

  6. Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and Diastolic Blood Pressure (DBP) <90 mmHg at Week 6

    The percentage of participants achieving averaged clinic SBP \<140 mmHg and DBP \<80 mmHg at Week 6 was evaluated.

    Time frame: Week 6

  7. Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 12

    The percentage of participants achieving averaged clinic SBP \<130 mmHg and DBP \<80 mmHg at Week 12 was evaluated.

    Time frame: Week 12

  8. Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 6

    The percentage of participants achieving averaged clinic SBP \<130 mmHg and DBP \<80 mmHg at Week 6 was evaluated.

    Time frame: Week 6

  9. Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 6

    Difference in change in average home SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6.

    Time frame: Week 6

  10. Difference in Change in Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 12

    Difference in change in average home DBP for GMRx2 vs each dual combination was evaluated from randomization to Week 12.

    Time frame: Week 12

  11. Difference in Change in Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 6

    Difference in change in average home DBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6.

    Time frame: Week 6

  12. Difference in Change in Trough Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12

    Difference in change in trough home SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 12. Trough values were measured before morning dose of the study medication.

    Time frame: Week 12

  13. Difference in Change in Trough Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 6

    Difference in change in trough home SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6. Trough values were measured before morning dose of the study medication.

    Time frame: Week 6

  14. Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <135 and Diastolic Blood Pressure (DBP) <85 mmHg at Week 12

    The percentage of participants achieving averaged home SBP \<135 mmHg and DBP \<85 mmHg at week 12 was calculated.

    Time frame: Week 12

  15. Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <135 and Diastolic Blood Pressure (DBP) <85 mmHg at Week 6

    The percentage of participants achieving averaged home SBP \<135 mmHg and DBP \<85 mmHg at Week 6 was evaluated.

    Time frame: Week 6

  16. Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 12

    The percentage of participants achieving averaged home SBP \<130 mmHg and DBP \<80 mmHg at Week 12 was evaluated.

    Time frame: Week 12

  17. Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 6

    The percentage of participants achieving averaged home SBP \<130 mmHg and DBP \<80 mmHg at Week 6 was evaluated.

    Time frame: Week 6

Other outcomes

  1. Percentage of Participants Discontinued Trial Medication Due to Adverse Event (AE)/Serious Adverse Event (SAE) From Randomization to Week 12

    The primary safety outcome is the proportion of participants who discontinued trial medication due to an AE or SAE from randomization to follow-up at Week 12.

    Time frame: Week 12

  2. Percentage of Participants Discontinued Trial Medication Due to Adverse Event (AE)/Serious Adverse Event (SAE) From Randomization to Week 6

    The secondary safety outcome is the proportion of participants who discontinued trial medication due to AE/SAE from randomization to follow-up at Week 6.

    Time frame: Week 6

  3. Percentage of Participants With a Serious Adverse Event (SAE) From Randomization to Week 12

    The secondary safety outcome is the proportion of participants with at least one SAE from randomization to follow-up at Week 12.

    Time frame: At Week 12

  4. Percentage of Participants With Serious Adverse Event (SAE) From Randomization to Week 6

    The secondary safety outcome is the proportion of participants with at least one SAE from randomization to follow-up at Week 6.

    Time frame: Week 6

  5. Percentage of Participants With Symptomatic Hypotension From Randomization to Week 12

    The secondary safety outcome is the proportion of participants who experienced at least one symptomatic hypotension episode from randomization to follow-up at Week 12.

    Time frame: Week 12

  6. Percentage of Participants With Symptomatic Hypotension From Randomization to Week 6

    The secondary safety outcome is the proportion of participants who experienced at least one symptomatic hypotension episode from randomization to follow-up at Week 6.

    Time frame: Week 6

  7. Percentage of Participants With Serum Sodium Concentration Below 135 mmol/l at Week 12

    The secondary safety outcome is the proportion of participants with serum sodium \<135 mmol/L at follow-up Week 12.

    Time frame: Week 12

  8. Percentage of Participants With Serum Sodium Concentration Below 135 mmol/l at Week 6

    The secondary safety outcome is the proportion of participants with serum sodium \<135 mmol/L at follow-up Week 6.

    Time frame: Week 6

  9. Percentage of Participants With Serum Sodium Concentration Above 145 mmol/l at Week 12

    The secondary safety outcome is the proportion of participants with serum sodium \>145 mmol/L at follow-up Week 12.

    Time frame: Week 12

  10. Percentage of Participants With Serum Sodium Concentration Above 145 mmol/l at Week 6

    The secondary safety outcome is the proportion of participants with serum sodium \>145 mmol/L at follow-up Week 6.

    Time frame: Week 6

  11. Percentage of Participants With Serum Potassium Concentration Below 3.5 mmol/l at Week 12

    The secondary safety outcome is the proportion of participants with serum potassium concentration \<3.5 mmol/L at follow-up Week 12.

    Time frame: Week 12

  12. Percentage of Participants With Serum Potassium Concentration Below 3.5 mmol/l at Week 6

    The secondary safety outcome is the proportion of participants with serum potassium concentration below 3.5 mmol/l at follow-up Week 6.

    Time frame: Week 6

  13. Percentage of Participants With Serum Potassium Concentration Above 5.5 mmol/l at Week 12

    The secondary safety outcome is proportion of participants with serum potassium concentration \>5.5 mmol/l at follow-up Week 12.

    Time frame: Week 12

  14. Percentage of Participants With Serum Potassium Concentration Above 5.5 mmol/l at Week 6

    The secondary safety outcome is proportion of participants with serum potassium concentration \>5.5 mmol/L at follow-up Week 6.

    Time frame: Week 6

  15. Percentage of Participants With Estimated Glomerular Filtration Rate (eGFR) Drop of Over 30% From Randomization to Week 12

    The secondary safety outcome was the proportion of participants with an eGFR drop of over 30% from randomization to follow-up at Week 12.

    Time frame: Week 12

  16. Percentage of Participants With Estimated Glomerular Filtration Rate (eGFR) Drop of Over 30% From Randomization to Week 6

    The secondary safety outcome is the proportion of participants with an eGFR drop of over 30% from randomization to follow-up at Week 6.

    Time frame: Week 6

  17. Percentage of Participants With Serum Sodium <135mmol/L or >145 mmol/L, and/or Serum Potassium <3.5 mmol/L or >5.5mmol/L at Follow-up Week 12

    The secondary safety outcome is the proportion of participants with serum sodium \<135mmol/L or \>145 mmol/L, and/or serum potassium \<3.5 mmol/L or \>5.5mmol/L at follow-up Week 12.

    Time frame: Week 12

  18. Percentage of Participants With Serum Sodium <135 mmol/L or >145 mmol/L, and/or Serum Potassium <3.5 mmol/L or >5.5 mmol/L at Week 6

    The secondary safety outcome is proportion of participants with serum sodium \<135 mmol/L or \>145 mmol/L, and/or serum potassium \<3.5 mmol/L or \>5.5 mmol/L at follow-up Week 6.

    Time frame: Week 6

  19. Percentage of Participants With Orthostatic Hypotension at Week 6

    The secondary safety outcome is the proportion of participants with orthostatic hypotension at follow-up Week 6.

    Time frame: Week 6

  20. Percentage of Participants With Orthostatic Hypotension at Week 12

    The secondary safety outcome is the proportion of participants with orthostatic hypotension at follow-up Week 12.

    Time frame: Week 12

  21. Percentage of Participants With Orthostatic Hypertension at Week 6

    The secondary safety outcome is the proportion of participants with orthostatic hypertension at follow-up Week 6.

    Time frame: Week 6

  22. Percentage of Participants With Orthostatic Hypertension at Week 12

    The secondary safety outcome is the proportion of participants with orthostatic hypertension at follow-up Week 12.

    Time frame: Week 12

07

Results

Posted Jun 3, 2025
Limitations and caveats
The trial included comparatively few participants with very high levels of blood pressure (BP), which makes direct comparison with previous trials challenging. The trial design did not allow a direct randomized comparison between ½ dose and standard dose combinations, or with other drugs and doses that are in common use. The option of non-uptitration after 6 weeks of half-dose regimens likely led to underestimation of the difference between standard dose regimens.

Participant flow

This trial was conducted at 83 study centers across 7 countries (Australia \[6\], Czech Republic \[2\], Great Britain \[25\], New Zealand \[2\], Poland \[9\], Sri Lanka \[14\], and USA \[25\]).

Single, Active run-in (4 Weeks)
Participant flow — Single, Active run-in (4 Weeks)
MilestoneGMRx2Dual - TADual - TIDual - AI
Started2244000
Completed1385000
Not completed859000
Double-blind
Participant flow — Double-blind
MilestoneGMRx2Dual - TADual - TIDual - AI
Started551282276276
Completed527273259259
Not completed2491717

Outcome measures

PrimaryDifference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12

The primary outcome measure is difference in change in average home SBP for GMRx2 vs each dual combination evaluated from randomization to Week 12. The change in home SBP from randomization for all treatment arms was measured using least squares (LS) mean change. The pairwise comparisons between GMRx2 and dual treatments in change in home SBP were estimated using LS means difference and are described in the statistical analysis.

Time frame:
Week 12
Reported as:
Least squares mean · mmHg
Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12
mmHgGMRx2Dual - TADual - TIDual - AI
Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12-4.0 ± 0.451.4 ± 0.60-1.5 ± 0.510.4 ± 0.62
Statistical analysis
  • GMRx2 vs Dual - TA · MIANALYZE procedure · p = <.0001 · Ls means difference: -5.44 · 95% CI -6.774 to -4.107
  • GMRx2 vs Dual - TI · MIANALYZE procedure · p = <.0001 · Ls means difference: -2.49 · 95% CI -3.723 to -1.251
  • GMRx2 vs Dual - AI · MIANALYZE procedure · p = <.0001 · Ls means difference: -4.42 · 95% CI -5.758 to -3.091
SecondaryDifference in Change in Clinic Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12

Difference in change in average clinic SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 12.

Time frame:
Week 12
Reported as:
Least squares mean · mmHg
Difference in Change in Clinic Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12
mmHgGMRx2Dual - TADual - TIDual - AI
Difference in Change in Clinic Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12-5.5 ± 0.550.1 ± 0.85-1.2 ± 1.020.9 ± 0.86
Statistical analysis
  • GMRx2 vs Dual - TA · Mixed Models Analysis · p = <.0001 · Ls means difference: -5.60 · 95% CI -7.307 to -3.902
  • GMRx2 vs Dual - TI · Mixed Models Analysis · p = 0.0005 · Ls means difference: -4.33 · 95% CI -6.718 to -1.933
  • GMRx2 vs Dual - AI · Mixed Models Analysis · p = <.0001 · Ls means difference: -6.33 · 95% CI -7.984 to -4.680
SecondaryDifference in Change in Clinic Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 6

Difference in change in average clinic SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6.

Time frame:
Week 6
Reported as:
Least squares mean · mmHg
Difference in Change in Clinic Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 6
mmHgGMRx2Dual - TADual - TIDual - AI
Difference in Change in Clinic Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 6-0.8 ± 0.504.2 ± 0.882.7 ± 0.964.5 ± 1.02
Statistical analysis
  • GMRx2 vs Dual - TA · Mixed Models Analysis · p = <.0001 · Ls means difference: -5.01 · 95% CI -6.703 to -3.317
  • GMRx2 vs Dual - TI · Mixed Models Analysis · p = 0.0002 · Ls means difference: -3.50 · 95% CI -5.293 to -1.700
  • GMRx2 vs Dual - AI · Mixed Models Analysis · p = <.0001 · Ls means difference: -5.35 · 95% CI -7.251 to -3.444
SecondaryDifference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 12

Difference in change in average clinic DBP for GMRx2 vs each dual combination was evaluated from randomization to Week 12.

Time frame:
Week 12
Reported as:
Least squares mean · mmHg
Difference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 12
mmHgGMRx2Dual - TADual - TIDual - AI
Difference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 12-3.4 ± 0.420.4 ± 0.520.2 ± 0.561.1 ± 0.61
Statistical analysis
  • GMRx2 vs Dual - TA · Mixed Models Analysis · p = <.0001 · Ls means difference: -3.72 · 95% CI -4.692 to -2.757
  • GMRx2 vs Dual - TI · Mixed Models Analysis · p = <.0001 · Ls means difference: -3.51 · 95% CI -4.897 to -2.128
  • GMRx2 vs Dual - AI · Mixed Models Analysis · p = <.0001 · Ls means difference: -4.50 · 95% CI -5.812 to -3.189
SecondaryDifference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 6

Difference in change in average clinic DBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6.

Time frame:
Week 6
Reported as:
Least squares mean · mmHg
Difference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 6
mmHgGMRx2Dual - TADual - TIDual - AI
Difference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 6-0.7 ± 0.381.7 ± 0.571.6 ± 0.573.1 ± 0.57
Statistical analysis
  • GMRx2 vs Dual - TA · Mixed Models Analysis · p = <.0001 · Ls means difference: -2.43 · 95% CI -3.392 to -1.469
  • GMRx2 vs Dual - TI · Mixed Models Analysis · p = <.0001 · Ls means difference: -2.29 · 95% CI -3.371 to -1.201
  • GMRx2 vs Dual - AI · Mixed Models Analysis · p = <.0001 · Ls means difference: -3.77 · 95% CI -4.882 to -2.664
SecondaryPercentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and Diastolic Blood Pressure (DBP) <90 mmHg at Week 12

The percentage of participants achieving averaged clinic SBP \<140 mmHg and DBP \<90 mmHg at Week 12 was evaluated.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and Diastolic Blood Pressure (DBP) <90 mmHg at Week 12
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and Diastolic Blood Pressure (DBP) <90 mmHg at Week 12407173167146
Statistical analysis
  • GMRx2 vs Dual - TA · Wald test · p = 0.0003 · Risk difference (rd): 12.52 · 95% CI 5.630 to 19.487
  • GMRx2 vs Dual - TI · Wald test · p = 0.0001 · Risk difference (rd): 13.36 · 95% CI 6.392 to 20.394
  • GMRx2 vs Dual - AI · Wald test · p = <.0001 · Risk difference (rd): 20.97 · 95% CI 13.812 to 28.013
SecondaryPercentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and Diastolic Blood Pressure (DBP) <90 mmHg at Week 6

The percentage of participants achieving averaged clinic SBP \<140 mmHg and DBP \<80 mmHg at Week 6 was evaluated.

Time frame:
Week 6
Reported as:
Count of participants · Participants
Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and Diastolic Blood Pressure (DBP) <90 mmHg at Week 6
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and Diastolic Blood Pressure (DBP) <90 mmHg at Week 6346148151122
Statistical analysis
  • GMRx2 vs Dual - TA · Wald test · p = 0.0044 · Risk difference (rd): 10.31 · 95% CI 3.044 to 17.535
  • GMRx2 vs Dual - TI · Wald test · p = 0.0262 · Risk difference (rd): 8.08 · 95% CI 0.804 to 15.373
  • GMRx2 vs Dual - AI · Wald test · p = <.0001 · Risk difference (rd): 18.59 · 95% CI 11.201 to 25.746
SecondaryPercentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 12

The percentage of participants achieving averaged clinic SBP \<130 mmHg and DBP \<80 mmHg at Week 12 was evaluated.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 12
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 12218657659
Statistical analysis
  • GMRx2 vs Dual - TA · Wald test · p = <.0001 · Risk difference (rd): 16.51 · 95% CI 9.707 to 22.837
  • GMRx2 vs Dual - TI · Wald test · p = 0.0004 · Risk difference (rd): 12.03 · 95% CI 4.982 to 18.658
  • GMRx2 vs Dual - AI · Wald test · p = <.0001 · Risk difference (rd): 18.19 · 95% CI 11.412 to 24.432
SecondaryPercentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 6

The percentage of participants achieving averaged clinic SBP \<130 mmHg and DBP \<80 mmHg at Week 6 was evaluated.

Time frame:
Week 6
Reported as:
Count of participants · Participants
Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 6
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 6167565950
Statistical analysis
  • GMRx2 vs Dual - TA · Wald test · p = 0.0007 · Risk difference (rd): 10.45 · 95% CI 3.993 to 16.433
  • GMRx2 vs Dual - TI · Wald test · p = 0.0046 · Risk difference (rd): 8.93 · 95% CI 2.337 to 15.058
  • GMRx2 vs Dual - AI · Wald test · p = <.0001 · Risk difference (rd): 12.19 · 95% CI 5.792 to 18.073
SecondaryDifference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 6

Difference in change in average home SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6.

Time frame:
Week 6
Reported as:
Least squares mean · mmHg
Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 6
mmHgGMRx2Dual - TADual - TIDual - AI
Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 6-0.9 ± 0.405.2 ± 0.572.1 ± 0.494.2 ± 0.56
Statistical analysis
  • GMRx2 vs Dual - TA · Mixed Models Analysis · p = <.0001 · Ls means difference: -6.11 · 95% CI -7.086 to -5.144
  • GMRx2 vs Dual - TI · Mixed Models Analysis · p = <.0001 · Ls means difference: -3.00 · 95% CI -4.060 to -1.932
  • GMRx2 vs Dual - AI · Mixed Models Analysis · p = <.0001 · Ls means difference: -5.09 · 95% CI -6.274 to -3.912
SecondaryDifference in Change in Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 12

Difference in change in average home DBP for GMRx2 vs each dual combination was evaluated from randomization to Week 12.

Time frame:
Week 12
Reported as:
Least squares mean · mmHg
Difference in Change in Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 12
mmHgGMRx2Dual - TADual - TIDual - AI
Difference in Change in Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 12-2.9 ± 0.280.5 ± 0.32-0.8 ± 0.350.7 ± 0.45
Statistical analysis
  • GMRx2 vs Dual - TA · Mixed Models Analysis · p = <.0001 · Ls means difference: -3.35 · 95% CI -4.069 to -2.632
  • GMRx2 vs Dual - TI · Mixed Models Analysis · p = <.0001 · Ls means difference: -2.10 · 95% CI -2.998 to -1.200
  • GMRx2 vs Dual - AI · Mixed Models Analysis · p = <.0001 · Ls means difference: -3.63 · 95% CI -4.617 to -2.649
SecondaryDifference in Change in Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 6

Difference in change in average home DBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6.

Time frame:
Week 6
Reported as:
Least squares mean · mmHg
Difference in Change in Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 6
mmHgGMRx2Dual - TADual - TIDual - AI
Difference in Change in Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 6-0.7 ± 0.292.5 ± 0.391.3 ± 0.402.5 ± 0.41
Statistical analysis
  • GMRx2 vs Dual - TA · Mixed Models Analysis · p = <.0001 · Ls means difference: -3.52 · 95% CI -4.137 to -2.908
  • GMRx2 vs Dual - TI · Mixed Models Analysis · p = <.0001 · Ls means difference: -2.09 · 95% CI -2.803 to -1.376
  • GMRx2 vs Dual - AI · Mixed Models Analysis · p = <.0001 · Ls means difference: -3.58 · 95% CI -4.446 to -2.713
SecondaryDifference in Change in Trough Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12

Difference in change in trough home SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 12. Trough values were measured before morning dose of the study medication.

Time frame:
Week 12
Reported as:
Least squares mean · mmHg
Difference in Change in Trough Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12
mmHgGMRx2Dual - TADual - TIDual - AI
Difference in Change in Trough Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12-4.0 ± 0.481.6 ± 0.59-2.1 ± 0.58-0.2 ± 0.63
Statistical analysis
  • GMRx2 vs Dual - TA · Mixed Models Analysis · p = <.0001 · Ls means difference: -5.58 · 95% CI -6.983 to -4.169
  • GMRx2 vs Dual - TI · Mixed Models Analysis · p = 0.0043 · Ls means difference: -1.91 · 95% CI -3.218 to -0.607
  • GMRx2 vs Dual - AI · Mixed Models Analysis · p = <.0001 · Ls means difference: -3.74 · 95% CI -5.214 to -2.274
SecondaryDifference in Change in Trough Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 6

Difference in change in trough home SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6. Trough values were measured before morning dose of the study medication.

Time frame:
Week 6
Reported as:
Least squares mean · mmHg
Difference in Change in Trough Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 6
mmHgGMRx2Dual - TADual - TIDual - AI
Difference in Change in Trough Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 6-0.9 ± 0.415.3 ± 0.661.8 ± 0.613.5 ± 0.57
Statistical analysis
  • GMRx2 vs Dual - TA · Mixed Models Analysis · p = <.0001 · Ls means difference: -6.25 · 95% CI -7.324 to -5.168
  • GMRx2 vs Dual - TI · Mixed Models Analysis · p = <.0001 · Ls means difference: -2.72 · 95% CI -3.941 to -1.507
  • GMRx2 vs Dual - AI · Mixed Models Analysis · p = <.0001 · Ls means difference: -4.43 · 95% CI -5.489 to -3.368
SecondaryPercentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <135 and Diastolic Blood Pressure (DBP) <85 mmHg at Week 12

The percentage of participants achieving averaged home SBP \<135 mmHg and DBP \<85 mmHg at week 12 was calculated.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <135 and Diastolic Blood Pressure (DBP) <85 mmHg at Week 12
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <135 and Diastolic Blood Pressure (DBP) <85 mmHg at Week 12398162176155
Statistical analysis
  • GMRx2 vs Dual - TA · Wald test · p = <.0001 · Risk difference (rd): 14.79 · 95% CI 7.749 to 21.824
  • GMRx2 vs Dual - TI · Wald test · p = 0.0146 · Risk difference (rd): 8.46 · 95% CI 1.580 to 15.501
  • GMRx2 vs Dual - AI · Wald test · p = <.0001 · Risk difference (rd): 16.07 · 95% CI 8.953 to 23.171
SecondaryPercentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <135 and Diastolic Blood Pressure (DBP) <85 mmHg at Week 6

The percentage of participants achieving averaged home SBP \<135 mmHg and DBP \<85 mmHg at Week 6 was evaluated.

Time frame:
Week 6
Reported as:
Count of participants · Participants
Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <135 and Diastolic Blood Pressure (DBP) <85 mmHg at Week 6
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <135 and Diastolic Blood Pressure (DBP) <85 mmHg at Week 6346126155123
Statistical analysis
  • GMRx2 vs Dual - TA · Wald test · p = <.0001 · Risk difference (rd): 18.11 · 95% CI 10.778 to 25.226
  • GMRx2 vs Dual - TI · Wald test · p = 0.0674 · Risk difference (rd): 6.64 · 95% CI -0.613 to 13.926
  • GMRx2 vs Dual - AI · Wald test · p = <.0001 · Risk difference (rd): 18.23 · 95% CI 10.839 to 25.392
SecondaryPercentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 12

The percentage of participants achieving averaged home SBP \<130 mmHg and DBP \<80 mmHg at Week 12 was evaluated.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 12
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 1230810912191
Statistical analysis
  • GMRx2 vs Dual - TA · Wald test · p = <.0001 · Risk difference (rd): 17.25 · 95% CI 9.902 to 24.286
  • GMRx2 vs Dual - TI · Wald test · p = 0.0010 · Risk difference (rd): 12.06 · 95% CI 4.632 to 19.293
  • GMRx2 vs Dual - AI · Wald test · p = <.0001 · Risk difference (rd): 22.93 · 95% CI 15.622 to 29.796
SecondaryPercentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 6

The percentage of participants achieving averaged home SBP \<130 mmHg and DBP \<80 mmHg at Week 6 was evaluated.

Time frame:
Week 6
Reported as:
Count of participants · Participants
Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 6
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 6247749079
Statistical analysis
  • GMRx2 vs Dual - TA · Wald test · p = <.0001 · Risk difference (rd): 18.59 · 95% CI 11.579 to 25.124
  • GMRx2 vs Dual - TI · Wald test · p = 0.0005 · Risk difference (rd): 12.22 · 95% CI 4.963 to 19.123
  • GMRx2 vs Dual - AI · Wald test · p = <.0001 · Risk difference (rd): 16.20 · 95% CI 9.060 to 22.914
Other pre-specifiedPercentage of Participants Discontinued Trial Medication Due to Adverse Event (AE)/Serious Adverse Event (SAE) From Randomization to Week 12

The primary safety outcome is the proportion of participants who discontinued trial medication due to an AE or SAE from randomization to follow-up at Week 12.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Participants Discontinued Trial Medication Due to Adverse Event (AE)/Serious Adverse Event (SAE) From Randomization to Week 12
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants Discontinued Trial Medication Due to Adverse Event (AE)/Serious Adverse Event (SAE) From Randomization to Week 1211344
Statistical analysis
  • GMRx2 vs Dual - TA · Risk difference (rd): 0.93 · 95% CI -1.529 to 2.768
  • GMRx2 vs Dual - TI · Risk difference (rd): 0.55 · 95% CI -2.098 to 2.475
  • GMRx2 vs Dual - AI · Risk difference (rd): 0.55 · 95% CI -2.098 to 2.475
Other pre-specifiedPercentage of Participants Discontinued Trial Medication Due to Adverse Event (AE)/Serious Adverse Event (SAE) From Randomization to Week 6

The secondary safety outcome is the proportion of participants who discontinued trial medication due to AE/SAE from randomization to follow-up at Week 6.

Time frame:
Week 6
Reported as:
Count of participants · Participants
Percentage of Participants Discontinued Trial Medication Due to Adverse Event (AE)/Serious Adverse Event (SAE) From Randomization to Week 6
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants Discontinued Trial Medication Due to Adverse Event (AE)/Serious Adverse Event (SAE) From Randomization to Week 65313
Other pre-specifiedPercentage of Participants With a Serious Adverse Event (SAE) From Randomization to Week 12

The secondary safety outcome is the proportion of participants with at least one SAE from randomization to follow-up at Week 12.

Time frame:
At Week 12
Reported as:
Count of participants · Participants
Percentage of Participants With a Serious Adverse Event (SAE) From Randomization to Week 12
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With a Serious Adverse Event (SAE) From Randomization to Week 1217676
Other pre-specifiedPercentage of Participants With Serious Adverse Event (SAE) From Randomization to Week 6

The secondary safety outcome is the proportion of participants with at least one SAE from randomization to follow-up at Week 6.

Time frame:
Week 6
Reported as:
Count of participants · Participants
Percentage of Participants With Serious Adverse Event (SAE) From Randomization to Week 6
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Serious Adverse Event (SAE) From Randomization to Week 612446
Other pre-specifiedPercentage of Participants With Symptomatic Hypotension From Randomization to Week 12

The secondary safety outcome is the proportion of participants who experienced at least one symptomatic hypotension episode from randomization to follow-up at Week 12.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Participants With Symptomatic Hypotension From Randomization to Week 12
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Symptomatic Hypotension From Randomization to Week 12325114
Other pre-specifiedPercentage of Participants With Symptomatic Hypotension From Randomization to Week 6

The secondary safety outcome is the proportion of participants who experienced at least one symptomatic hypotension episode from randomization to follow-up at Week 6.

Time frame:
Week 6
Reported as:
Count of participants · Participants
Percentage of Participants With Symptomatic Hypotension From Randomization to Week 6
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Symptomatic Hypotension From Randomization to Week 615312
Other pre-specifiedPercentage of Participants With Serum Sodium Concentration Below 135 mmol/l at Week 12

The secondary safety outcome is the proportion of participants with serum sodium \<135 mmol/L at follow-up Week 12.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Participants With Serum Sodium Concentration Below 135 mmol/l at Week 12
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Serum Sodium Concentration Below 135 mmol/l at Week 124091910
Statistical analysis
  • GMRx2 vs Dual - TA · Risk difference (rd): 4.07 · 95% CI 0.494 to 7.116
  • GMRx2 vs Dual - TI · Risk difference (rd): 0.38 · 95% CI -3.927 to 4.020
  • GMRx2 vs Dual - AI · Risk difference (rd): 3.64 · 95% CI -0.070 to 6.764
Other pre-specifiedPercentage of Participants With Serum Sodium Concentration Below 135 mmol/l at Week 6

The secondary safety outcome is the proportion of participants with serum sodium \<135 mmol/L at follow-up Week 6.

Time frame:
Week 6
Reported as:
Count of participants · Participants
Percentage of Participants With Serum Sodium Concentration Below 135 mmol/l at Week 6
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Serum Sodium Concentration Below 135 mmol/l at Week 6266811
Statistical analysis
  • GMRx2 vs Dual - TA · Risk difference (rd): 2.59 · 95% CI -0.500 to 5.136
  • GMRx2 vs Dual - TI · Risk difference (rd): 1.82 · 95% CI -1.513 to 4.517
  • GMRx2 vs Dual - AI · Risk difference (rd): 0.73 · 95% CI -2.855 to 3.633
Other pre-specifiedPercentage of Participants With Serum Sodium Concentration Above 145 mmol/l at Week 12

The secondary safety outcome is the proportion of participants with serum sodium \>145 mmol/L at follow-up Week 12.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Participants With Serum Sodium Concentration Above 145 mmol/l at Week 12
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Serum Sodium Concentration Above 145 mmol/l at Week 1229151613
Statistical analysis
  • GMRx2 vs Dual - TA · Risk difference (rd): -0.06 · 95% CI -3.911 to 3.129
  • GMRx2 vs Dual - TI · Risk difference (rd): -0.53 · 95% CI -4.519 to 2.744
  • GMRx2 vs Dual - AI · Risk difference (rd): 0.55 · 95% CI -3.228 to 3.647
Other pre-specifiedPercentage of Participants With Serum Sodium Concentration Above 145 mmol/l at Week 6

The secondary safety outcome is the proportion of participants with serum sodium \>145 mmol/L at follow-up Week 6.

Time frame:
Week 6
Reported as:
Count of participants · Participants
Percentage of Participants With Serum Sodium Concentration Above 145 mmol/l at Week 6
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Serum Sodium Concentration Above 145 mmol/l at Week 62614815
Statistical analysis
  • GMRx2 vs Dual - TA · Risk difference (rd): -0.25 · 95% CI -3.993 to 2.816
  • GMRx2 vs Dual - TI · Risk difference (rd): 1.82 · 95% CI -1.513 to 4.517
  • GMRx2 vs Dual - AI · Risk difference (rd): -0.72 · 95% CI -4.596 to 2.440
Other pre-specifiedPercentage of Participants With Serum Potassium Concentration Below 3.5 mmol/l at Week 12

The secondary safety outcome is the proportion of participants with serum potassium concentration \<3.5 mmol/L at follow-up Week 12.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Participants With Serum Potassium Concentration Below 3.5 mmol/l at Week 12
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Serum Potassium Concentration Below 3.5 mmol/l at Week 123701335
Statistical analysis
  • GMRx2 vs Dual - TA · Risk difference (rd): 6.72 · 95% CI 4.196 to 9.222
  • GMRx2 vs Dual - TI · Risk difference (rd): 2.00 · 95% CI -1.883 to 5.257
  • GMRx2 vs Dual - AI · Risk difference (rd): -5.97 · 95% CI -10.979 to -1.600
Other pre-specifiedPercentage of Participants With Serum Potassium Concentration Below 3.5 mmol/l at Week 6

The secondary safety outcome is the proportion of participants with serum potassium concentration below 3.5 mmol/l at follow-up Week 6.

Time frame:
Week 6
Reported as:
Count of participants · Participants
Percentage of Participants With Serum Potassium Concentration Below 3.5 mmol/l at Week 6
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Serum Potassium Concentration Below 3.5 mmol/l at Week 62751021
Statistical analysis
  • GMRx2 vs Dual - TA · Risk difference (rd): 3.13 · 95% CI 0.123 to 5.632
  • GMRx2 vs Dual - TI · Risk difference (rd): 1.28 · 95% CI -2.245 to 4.134
  • GMRx2 vs Dual - AI · Risk difference (rd): -2.71 · 95% CI -6.968 to 0.819
Other pre-specifiedPercentage of Participants With Serum Potassium Concentration Above 5.5 mmol/l at Week 12

The secondary safety outcome is proportion of participants with serum potassium concentration \>5.5 mmol/l at follow-up Week 12.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Participants With Serum Potassium Concentration Above 5.5 mmol/l at Week 12
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Serum Potassium Concentration Above 5.5 mmol/l at Week 125001
Statistical analysis
  • GMRx2 vs Dual - TA · Risk difference (rd): 0.91 · 95% CI -0.863 to 2.231
  • GMRx2 vs Dual - TI · Risk difference (rd): 0.91 · 95% CI -0.897 to 2.231
  • GMRx2 vs Dual - AI · Risk difference (rd): 0.55 · 95% CI -1.494 to 1.913
Other pre-specifiedPercentage of Participants With Serum Potassium Concentration Above 5.5 mmol/l at Week 6

The secondary safety outcome is proportion of participants with serum potassium concentration \>5.5 mmol/L at follow-up Week 6.

Time frame:
Week 6
Reported as:
Count of participants · Participants
Percentage of Participants With Serum Potassium Concentration Above 5.5 mmol/l at Week 6
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Serum Potassium Concentration Above 5.5 mmol/l at Week 62110
Statistical analysis
  • GMRx2 vs Dual - TA · Risk difference (rd): 0.01 · 95% CI -1.931 to 1.149
  • GMRx2 vs Dual - TI · Risk difference (rd): 0.00 · 95% CI -1.979 to 1.143
  • GMRx2 vs Dual - AI · Risk difference (rd): 0.36 · 95% CI -1.374 to 1.453
Other pre-specifiedPercentage of Participants With Estimated Glomerular Filtration Rate (eGFR) Drop of Over 30% From Randomization to Week 12

The secondary safety outcome was the proportion of participants with an eGFR drop of over 30% from randomization to follow-up at Week 12.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Participants With Estimated Glomerular Filtration Rate (eGFR) Drop of Over 30% From Randomization to Week 12
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Estimated Glomerular Filtration Rate (eGFR) Drop of Over 30% From Randomization to Week 128311
Statistical analysis
  • GMRx2 vs Dual - TA · Risk difference (rd): 0.39 · 95% CI -2.014 to 2.087
  • GMRx2 vs Dual - TI · Risk difference (rd): 1.09 · 95% CI -1.015 to 2.633
  • GMRx2 vs Dual - AI · Risk difference (rd): 1.09 · 95% CI -1.015 to 2.633
Other pre-specifiedPercentage of Participants With Estimated Glomerular Filtration Rate (eGFR) Drop of Over 30% From Randomization to Week 6

The secondary safety outcome is the proportion of participants with an eGFR drop of over 30% from randomization to follow-up at Week 6.

Time frame:
Week 6
Reported as:
Count of participants · Participants
Percentage of Participants With Estimated Glomerular Filtration Rate (eGFR) Drop of Over 30% From Randomization to Week 6
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Estimated Glomerular Filtration Rate (eGFR) Drop of Over 30% From Randomization to Week 65343
Statistical analysis
  • GMRx2 vs Dual - TA · Risk difference (rd): -0.16 · 95% CI -2.501 to 1.385
  • GMRx2 vs Dual - TI · Risk difference (rd): -0.54 · 95% CI -3.078 to 1.108
  • GMRx2 vs Dual - AI · Risk difference (rd): -0.18 · 95% CI -2.571 to 1.370
Other pre-specifiedPercentage of Participants With Serum Sodium <135mmol/L or >145 mmol/L, and/or Serum Potassium <3.5 mmol/L or >5.5mmol/L at Follow-up Week 12

The secondary safety outcome is the proportion of participants with serum sodium \<135mmol/L or \>145 mmol/L, and/or serum potassium \<3.5 mmol/L or \>5.5mmol/L at follow-up Week 12.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Participants With Serum Sodium <135mmol/L or >145 mmol/L, and/or Serum Potassium <3.5 mmol/L or >5.5mmol/L at Follow-up Week 12
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Serum Sodium <135mmol/L or >145 mmol/L, and/or Serum Potassium <3.5 mmol/L or >5.5mmol/L at Follow-up Week 12105244457
Statistical analysis
  • GMRx2 vs Dual - TA · Risk difference (rd): 10.55 · 95% CI 5.422 to 15.138
  • GMRx2 vs Dual - TI · Risk difference (rd): 3.11 · 95% CI -2.776 to 8.490
  • GMRx2 vs Dual - AI · Risk difference (rd): -1.60 · 95% CI -7.807 to 4.174
Other pre-specifiedPercentage of Participants With Serum Sodium <135 mmol/L or >145 mmol/L, and/or Serum Potassium <3.5 mmol/L or >5.5 mmol/L at Week 6

The secondary safety outcome is proportion of participants with serum sodium \<135 mmol/L or \>145 mmol/L, and/or serum potassium \<3.5 mmol/L or \>5.5 mmol/L at follow-up Week 6.

Time frame:
Week 6
Reported as:
Count of participants · Participants
Percentage of Participants With Serum Sodium <135 mmol/L or >145 mmol/L, and/or Serum Potassium <3.5 mmol/L or >5.5 mmol/L at Week 6
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Serum Sodium <135 mmol/L or >145 mmol/L, and/or Serum Potassium <3.5 mmol/L or >5.5 mmol/L at Week 679252644
Statistical analysis
  • GMRx2 vs Dual - TA · Risk difference (rd): 5.47 · 95% CI 0.531 to 9.867
  • GMRx2 vs Dual - TI · Risk difference (rd): 4.92 · 95% CI -0.136 to 9.397
  • GMRx2 vs Dual - AI · Risk difference (rd): -1.60 · 95% CI -7.299 to 3.567
Other pre-specifiedPercentage of Participants With Orthostatic Hypotension at Week 6

The secondary safety outcome is the proportion of participants with orthostatic hypotension at follow-up Week 6.

Time frame:
Week 6
Reported as:
Count of participants · Participants
Percentage of Participants With Orthostatic Hypotension at Week 6
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Orthostatic Hypotension at Week 627142015
Statistical analysis
  • GMRx2 vs Dual - TA · Wald test · p = 0.9677 · Risk difference (rd): -0.06 · 95% CI -3.825 to 3.019
  • GMRx2 vs Dual - TI · Wald test · p = 0.1952 · Risk difference (rd): -2.35 · 95% CI -6.550 to 1.125
  • GMRx2 vs Dual - AI · Wald test · p = 0.7453 · Risk difference (rd): -0.53 · 95% CI -4.428 to 2.642
Other pre-specifiedPercentage of Participants With Orthostatic Hypotension at Week 12

The secondary safety outcome is the proportion of participants with orthostatic hypotension at follow-up Week 12.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Participants With Orthostatic Hypotension at Week 12
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Orthostatic Hypotension at Week 1228142120
Statistical analysis
  • GMRx2 vs Dual - TA · Wald test · p = 0.9415 · Risk difference (rd): 0.12 · 95% CI -3.657 to 3.222
  • GMRx2 vs Dual - TI · Wald test · p = 0.1719 · Risk difference (rd): -2.53 · 95% CI -6.799 to 1.019
  • GMRx2 vs Dual - AI · Wald test · p = 0.2342 · Risk difference (rd): -2.16 · 95% CI -6.380 to 1.326
Other pre-specifiedPercentage of Participants With Orthostatic Hypertension at Week 6

The secondary safety outcome is the proportion of participants with orthostatic hypertension at follow-up Week 6.

Time frame:
Week 6
Reported as:
Count of participants · Participants
Percentage of Participants With Orthostatic Hypertension at Week 6
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Orthostatic Hypertension at Week 6119695766
Statistical analysis
  • GMRx2 vs Dual - TA · Wald test · p = 0.3548 · Risk difference (rd): -2.87 · 95% CI -9.316 to 3.215
  • GMRx2 vs Dual - TI · Wald test · p = 0.7529 · Risk difference (rd): 0.94 · 95% CI -5.356 to 6.800
  • GMRx2 vs Dual - AI · Wald test · p = 0.4563 · Risk difference (rd): -2.32 · 95% CI -8.791 to 3.772
Other pre-specifiedPercentage of Participants With Orthostatic Hypertension at Week 12

The secondary safety outcome is the proportion of participants with orthostatic hypertension at follow-up Week 12.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Participants With Orthostatic Hypertension at Week 12
ParticipantsGMRx2Dual - TADual - TIDual - AI
Percentage of Participants With Orthostatic Hypertension at Week 12112576657
Statistical analysis
  • GMRx2 vs Dual - TA · Wald test · p = 0.9691 · Risk difference (rd): 0.11 · 95% CI -6.063 to 5.859
  • GMRx2 vs Dual - TI · Wald test · p = 0.2454 · Risk difference (rd): -3.59 · 95% CI -10.018 to 2.462
  • GMRx2 vs Dual - AI · Wald test · p = 0.9130 · Risk difference (rd): -0.33 · 95% CI -6.583 to 5.488

Adverse events

Collected over 16 weeks. Non-serious events are listed at a 0.2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Not Randomized0/859 (0%)15/859 (1.7%)136/859 (15.8%)
GMRx20/551 (0%)22/551 (4%)306/551 (55.5%)
Dual - TA0/282 (0%)11/282 (3.9%)139/282 (49.3%)
Dual - TI0/276 (0%)14/276 (5.1%)142/276 (51.4%)
Dual - AI0/276 (0%)8/276 (2.9%)136/276 (49.3%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventNot RandomizedGMRx2Dual - TADual - TIDual - AI
COVID-19Infections and infestations9/85914/5516/28212/2767/276
Blood uric acid increasedInvestigations0/8590/5510/2821/2760/276
Non-cardiac chest painGeneral disorders0/8590/5510/2821/2760/276
Acute myocardial infarctionCardiac disorders0/8590/5510/2821/2760/276
Lower respiratory tract infectionInfections and infestations0/8590/5510/2821/2760/276
Respiratory failureRespiratory, thoracic and mediastinal disorders0/8590/5510/2821/2760/276
Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders0/8590/5510/2821/2760/276
BursitisMusculoskeletal and connective tissue disorders0/8590/5510/2821/2760/276
Cervical radiculopathyNervous system disorders0/8590/5510/2820/2761/276
HyperglycaemiaMetabolism and nutrition disorders0/8590/5510/2820/2761/276
Most frequent other events
Showing 10 of 31
Most frequent other events
EventNot RandomizedGMRx2Dual - TADual - TIDual - AI
Blood glucose increasedInvestigations0/85942/55115/28219/27626/276
Blood uric acid increasedInvestigations0/85937/5519/28219/27623/276
HypokalemiaMetabolism and nutrition disorders10/85928/5516/2828/27620/276
Blood potassium decreasedInvestigations0/85914/5512/2828/27617/276
Blood cholesterol increasedInvestigations0/85922/55117/2829/2764/276
HyponatremiaMetabolism and nutrition disorders19/85928/55112/28214/27616/276
HeadacheNervous system disorders14/85930/55110/28213/2769/276
Glomerular filtration rate decreasedInvestigations10/85920/5519/28215/27614/276
Blood creatinine increasedInvestigations0/85928/5518/28212/2764/276
DizzinessNervous system disorders22/85928/55110/2824/2763/276

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GMRx2Dual - TADual - TIDual - AITotal
Mean59.1 ± 11.2858.7 ± 11.4159.2 ± 10.2958.9 ± 11.3259.0 ± 11.12
Sex: Female, Male
Sex: Female, Male(Participants)GMRx2Dual - TADual - TIDual - AITotal
Female276145143148712
Male275137133128673
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GMRx2Dual - TADual - TIDual - AITotal
Hispanic or Latino63313035159
Not Hispanic or Latino4872502462411224
Unknown or Not Reported11002
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GMRx2Dual - TADual - TIDual - AITotal
American Indian or Alaska Native01001
Asian272135132134673
Native Hawaiian or Other Pacific Islander23319
Black or African American3011131670
White246132128125631
More than one race10001
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)GMRx2Dual - TADual - TIDual - AITotal
New Zealand844420
United States83444249218
Sri Lanka260131128127646
Czechia423211
Poland42219
United Kingdom138737268351
Australia54262525130
Body Mass Index (BMI)
Body Mass Index (BMI)(Kg/m^2)GMRx2Dual - TADual - TIDual - AITotal
Mean28.87 ± 5.68828.68 ± 5.73529.05 ± 5.68628.82 ± 6.02228.86 ± 5.761
Weight
Weight(Kg)GMRx2Dual - TADual - TIDual - AITotal
Mean79.09 ± 20.71478.19 ± 19.99579.38 ± 20.62378.03 ± 20.85978.75 ± 20.565
Height
Height(cm)GMRx2Dual - TADual - TIDual - AITotal
Mean164.72 ± 11.054164.47 ± 10.659164.54 ± 11.566163.84 ± 11.702164.46 ± 11.204

5 further baseline measures are reported on the registry.

08

Study locations

89 sites
  • Elite Clinical Studies
    Phoenix, Arizona 85018, United States
  • Headlands Research
    Scottsdale, Arizona 85260, United States
  • Quality of Life Medical & Research Associates
    Tucson, Arizona 85712, United States
  • Valiance Clinical Research
    S. Gate, California 90280, United States
  • Valiance Clinical Research
    Tarzana, California 91356, United States
  • Clinical Research of Brandon
    Brandon, Florida 33511, United States
  • Inpatient Research Clinic
    Hialeah, Florida 33013, United States
  • Multi-Speciality Research Associates
    Lake City, Florida 32055, United States
  • Suncoast Research Group
    Miami, Florida 33135, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • Ocala Research Institute
    Ocala, Florida 34471, United States
  • Suncoast Research Associates
    Saint Petersburg, Florida 33173, United States
  • Accel Research
    Saint Petersburg, Florida 33709, United States
  • Precision Research Center
    Tampa, Florida 33603, United States
  • Meridian Clinical Research
    Savannah, Georgia 31406, United States
  • Buckhead Primary Care Research
    Snellville, Georgia 30078, United States
  • Loyola University
    Maywood, Illinois 60153, United States
  • Meridian Clinical Research
    Baton Rouge, Louisiana 70809, United States
  • Meridian Clinical Research
    Endwell, New York 13760, United States
  • Javarra Research
    Charlotte, North Carolina 28210, United States
  • East Carolina University
    Greenville, North Carolina 27834, United States
  • The University of Tennessee Health Science Center
    Memphis, Tennessee 38105, United States
  • ACRC Trials - Southwest Medical Village
    Austin, Texas 78735, United States
  • ACRC Trials - Premier Family Physicians
    Austin, Texas 78746, United States
  • ACRC Trials - Family Medicine Associates of Texas
    Carlton, Texas 75010, United States
  • Synergy Groups Medical
    Houston, Texas 77036, United States
  • Synergy Groups Medical
    Houston, Texas 77087, United States
  • Synergy Groups Medical
    Missouri City, Texas 77459, United States
  • North Hills Medical Research
    North Richland Hills, Texas 76180, United States
  • ACRC Trials - Village Health Partners
    Plano, Texas 75093, United States
  • Meridian Clinical Research
    Portsmouth, Virginia 23703, United States
  • Castle Hill Medical Centre
    Castle Hill, New South Wales 2154, Australia
  • Princess Alexandra Hospital - Hypertension Unit
    Brisbane, Queensland 4102, Australia
  • Hudson Institute of Medical Research
    Clayton, Victoria 3168, Australia
  • Barwon Health, Geelong University Hospital
    Geelong, Victoria 3220, Australia
  • Curtin University
    Bentley, Western Australia 6102, Australia
  • Royal Perth Hospital
    Perth, Western Australia 6000, Australia
  • EDUMED, s.r.o
    Broumov, Kralovehradsky 550 01, Czechia
  • EDUMED, s.r.o
    Jaroměř, Kralovehradsky 551 01, Czechia
  • Private Cardiologic Ambulance, Medicus Services s.r.o
    Brandýs Nad Labem, Stredocesky 250 01, Czechia
  • Middlemore Clinical Trials
    Otahuhu, Auckland 2025, New Zealand
  • Gisborne Hospital
    Gisborne, 4040, New Zealand
  • Medical University of Gdansk
    Gdańsk, Gdansk 80-214, Poland
  • Futuremeds
    Wrocław, Wroclaw 50-088, Poland
  • Medical University of Gdansk
    Gdańsk, Poland
  • Pratia Katowice Medical Centre
    Katowice, 40-081, Poland
  • Pratia Katowice Medical Centre
    Katowice, Poland
  • Nowodworskie Medical Center
    Nowy Dwór Mazowiecki, Poland
  • Medical Center Pratia Poznan
    Poznań, Poland
  • ETG Network
    Skierniewice, 96-100, Poland
  • ETG Network
    Skierniewice, Poland
  • The Medical University of Warsaw
    Warsaw, Poland
  • EMC Instytut Medyczny S.A
    Wrocław, Poland
  • Futuremeds
    Wrocław, Poland
  • Clinical Medicine Academic & Research Centre
    Colombo, 10-01000, Sri Lanka
  • Institute of Cardiology, National Hospital of Sri Lanka
    Colombo, 10-01000, Sri Lanka
  • Colombo South Teaching Hospital
    Dehiwala, 10350, Sri Lanka
  • Karapitiya Teaching Hospital
    Galle, 80000, Sri Lanka
  • Jafna Teaching Hospital
    Jaffna, 40000, Sri Lanka
  • Kandy National Hospital
    Kandy, 20000, Sri Lanka
  • Kurunegala Teaching Hospital
    Kurunegala, 60000, Sri Lanka
  • Negombo District General Hospital
    Negombo, 11500, Sri Lanka
  • Sri Jayawardenapura General Hospital
    Nugegoda, 10250, Sri Lanka
  • Colombo North Teaching Hospital
    Ragama, 11010, Sri Lanka
  • Steploe Medical Centre
    Soham, Cambridgeshire CB7 5JD, United Kingdom
  • Ashfields Primary Care Centre
    Sandbach, Cheshire CW11 1EQ, United Kingdom
  • Newquay Medical
    Newquay, Cornwall TR7 1RU, United Kingdom
  • Royal Primary care Ashgate
    Chesterfield, Derbyshire S40 4AA, United Kingdom
  • Carmel Medical Practice
    Darlington, Durham DL3 8SQ, United Kingdom
  • PRC Leciester
    Leicester, East Midlands LE5 4PW, United Kingdom
  • Portmill Surgery
    Hitchin, Herts. SG49TH, United Kingdom
  • Layton Medical Centre
    Blackpool, Lancashire FY3 7EN, United Kingdom
  • Waterloo Medical Centre
    Blackpool, Lancashire FY4 3AD, United Kingdom
  • Burbage Surgery
    Hinckley, Leicestershire LE10 2SE, United Kingdom
  • Belmont Health Centre
    Harrow, London HA3 7LT, United Kingdom
  • The Adam Practice
    Upton, Poole BH165PW, United Kingdom
  • Heart of bath Medical Partnership
    Bath, Somerset BA2 3HT, United Kingdom
  • West Walk Surgery
    Bristol, Somerset BS37 4AX, United Kingdom
  • Tyntesfield Medical Group
    Nailsea, Somerset BS48 1BZ, United Kingdom
  • Clifton Medical centre
    Rotherham, South Yorkshire S65 1DA, United Kingdom
  • Ely Bridge
    Cardiff, Wales CV32 4RA, United Kingdom
  • Atherstone Surgery
    Atherstone, Warwickshire CV9 1EU, United Kingdom
  • Lakeside Surgery
    Coventry, West Midlands CV3 6NF, United Kingdom
  • Sherbourne Medical Centre
    Leamington Spa, West Midlands CV324RA, United Kingdom
  • Hathaway Surgery
    Chippenham, Wiltshire SN14 6GT, United Kingdom
  • Rowden Surgery
    Chippenham, Wiltshire SN15 2SB, United Kingdom
  • Trowbridge Health Centre
    Trowbridge, Wiltshire BA14 8LW, United Kingdom
  • Bart's NHS Trust
    London, EC1M6BO, United Kingdom
  • Ecclesfield group Practice
    Sheffield, S35 9XQ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — If the sponsor receives a request for study data, then such requests will be reviewed by sponsor following completion of regulatory submissions and review, and with support from members of the GMRX2 steering committee who will advise on the scientific merit and integrity of the proposed analysis.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Aug 2023, 25 months.

Results were first posted in Jun 2025, 1 year 9 months after primary completion.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 25 months is above that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2020
First posted
Aug 19, 2020
StartActual
Jul 9, 2021
Primary completionActual
Aug 11, 2023
CompletionActual
Sep 1, 2023
Results first posted
Jun 3, 2025
Last update
Jun 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04518293
Lead sponsor
George Medicines PTY Limited
Responsible party
Sponsor
First posted
Aug 19, 2020
Start date
Jul 9, 2021
Primary completion
Aug 11, 2023
Completion
Sep 1, 2023
Results posted
Jun 3, 2025
Last update
Jun 3, 2025

Study contacts

Anthony Rodgers, Professor
principal investigator · The George Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telmisartan

Start the discussion